FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2994622122> ?p ?o ?g. }

• W2994622122 endingPage "653.e1" @default.
• W2994622122 startingPage "646" @default.
• W2994622122 abstract "BackgroundCurrent childhood asthma therapies have little effect on lung function trajectory.ObjectiveWe sought to determine whether mouse allergen exposure reduction is associated with lung function growth in mouse-sensitized/exposed asthmatic children.MethodsThree hundred fifty mouse-sensitized/exposed asthmatic children (5-17 years old) were enrolled in a 1-year randomized trial of integrated pest management plus education versus education alone. Prebronchodilator/postbronchodilator spirometry was performed at baseline and 6 and 12 months, and bedroom floor mouse allergen levels were measured every 3 months. Mouse allergen reduction was defined as a 75% or greater decrease in mouse allergen levels from baseline. Treatment groups were combined for analyses because there were no differences in outcomes between groups. Changes in lung function over time were modeled, adjusting for age, sex, race, atopy, group, and bronchodilator reversibility and including an interaction term (allergen reduction*time).ResultsThe study population was predominantly black (79.4%) and low income (66.3% [<$30,000]). At baseline, the median mouse allergen level was 5.7 μg/g (interquartile range, 1.5-22.8 μg/g), and the mean (SD) prebronchodilator FEV1/forced vital capacity ratio was 80.2% (9.0%). Ninety-two (26.3%) participants had 75% or greater reduction in mouse allergen levels. For a 10-year-old black boy, 75% or greater allergen reduction was associated with an increase in prebronchodilator FEV1 of 238 mL/y (95% CI, 177-299 mL/y), whereas less than 75% allergen reduction was associated with an increase in prebronchodilator FEV1 of 131 mL/y (95% CI, 97-166 mL/y). Estimated differences in prebronchodilator and postbronchodilator FEV1 growth were as follows: 107 mL/y (95% CI, 37-177 mL/y; Pint = .003) and 48 mL/y (95% CI, −17 to 113 mL/y; Pint = .15), respectively. Estimated differences in prebronchodilator and postbronchodilator forced expiratory flow at 25% to 75% of vital capacity growth were as follows: 182 mL/y (95% CI, 61-304 mL/y; Pint = .003) and 181 mL/y (95% CI, 48-314 mL/y; Pint = .008), respectively.ConclusionMouse allergen reduction is associated with greater increases in prebronchodilator FEV1 and prebronchodilator/postbronchodilator forced expiratory flow at 25% to 75% of vital capacity over 1 year among sensitized/exposed asthmatic children. Current childhood asthma therapies have little effect on lung function trajectory. We sought to determine whether mouse allergen exposure reduction is associated with lung function growth in mouse-sensitized/exposed asthmatic children. Three hundred fifty mouse-sensitized/exposed asthmatic children (5-17 years old) were enrolled in a 1-year randomized trial of integrated pest management plus education versus education alone. Prebronchodilator/postbronchodilator spirometry was performed at baseline and 6 and 12 months, and bedroom floor mouse allergen levels were measured every 3 months. Mouse allergen reduction was defined as a 75% or greater decrease in mouse allergen levels from baseline. Treatment groups were combined for analyses because there were no differences in outcomes between groups. Changes in lung function over time were modeled, adjusting for age, sex, race, atopy, group, and bronchodilator reversibility and including an interaction term (allergen reduction*time). The study population was predominantly black (79.4%) and low income (66.3% [<$30,000]). At baseline, the median mouse allergen level was 5.7 μg/g (interquartile range, 1.5-22.8 μg/g), and the mean (SD) prebronchodilator FEV1/forced vital capacity ratio was 80.2% (9.0%). Ninety-two (26.3%) participants had 75% or greater reduction in mouse allergen levels. For a 10-year-old black boy, 75% or greater allergen reduction was associated with an increase in prebronchodilator FEV1 of 238 mL/y (95% CI, 177-299 mL/y), whereas less than 75% allergen reduction was associated with an increase in prebronchodilator FEV1 of 131 mL/y (95% CI, 97-166 mL/y). Estimated differences in prebronchodilator and postbronchodilator FEV1 growth were as follows: 107 mL/y (95% CI, 37-177 mL/y; Pint = .003) and 48 mL/y (95% CI, −17 to 113 mL/y; Pint = .15), respectively. Estimated differences in prebronchodilator and postbronchodilator forced expiratory flow at 25% to 75% of vital capacity growth were as follows: 182 mL/y (95% CI, 61-304 mL/y; Pint = .003) and 181 mL/y (95% CI, 48-314 mL/y; Pint = .008), respectively. Mouse allergen reduction is associated with greater increases in prebronchodilator FEV1 and prebronchodilator/postbronchodilator forced expiratory flow at 25% to 75% of vital capacity over 1 year among sensitized/exposed asthmatic children." @default.
• W2994622122 created "2019-12-26" @default.
• W2994622122 creator A5002714937 @default.
• W2994622122 creator A5023824672 @default.
• W2994622122 creator A5026415610 @default.
• W2994622122 creator A5041039670 @default.
• W2994622122 creator A5043482439 @default.
• W2994622122 creator A5043763838 @default.
• W2994622122 creator A5048374080 @default.
• W2994622122 creator A5062887081 @default.
• W2994622122 creator A5075233055 @default.
• W2994622122 creator A5076055234 @default.
• W2994622122 creator A5076072202 @default.
• W2994622122 creator A5084365337 @default.
• W2994622122 date "2020-02-01" @default.
• W2994622122 modified "2023-10-16" @default.
• W2994622122 title "Reduction in mouse allergen exposure is associated with greater lung function growth" @default.
• W2994622122 cites W129276365 @default.
• W2994622122 cites W1975754118 @default.
• W2994622122 cites W1979235985 @default.
• W2994622122 cites W1997242991 @default.
• W2994622122 cites W2006193046 @default.
• W2994622122 cites W2018245697 @default.
• W2994622122 cites W2021014872 @default.
• W2994622122 cites W2021339739 @default.
• W2994622122 cites W2051781957 @default.
• W2994622122 cites W2064495388 @default.
• W2994622122 cites W2080585191 @default.
• W2994622122 cites W2094354458 @default.
• W2994622122 cites W2097941784 @default.
• W2994622122 cites W2104537618 @default.
• W2994622122 cites W2108678383 @default.
• W2994622122 cites W2121847767 @default.
• W2994622122 cites W2124723617 @default.
• W2994622122 cites W2132372821 @default.
• W2994622122 cites W2137194992 @default.
• W2994622122 cites W2138738847 @default.
• W2994622122 cites W2147459392 @default.
• W2994622122 cites W2147608146 @default.
• W2994622122 cites W2147786371 @default.
• W2994622122 cites W2150237519 @default.
• W2994622122 cites W2150373878 @default.
• W2994622122 cites W2151571379 @default.
• W2994622122 cites W2154704691 @default.
• W2994622122 cites W2160056887 @default.
• W2994622122 cites W2160896282 @default.
• W2994622122 cites W2164740939 @default.
• W2994622122 cites W2201710109 @default.
• W2994622122 cites W2357940608 @default.
• W2994622122 cites W2552850038 @default.
• W2994622122 cites W2591577397 @default.
• W2994622122 cites W2604596332 @default.
• W2994622122 cites W2614171167 @default.
• W2994622122 cites W2768767566 @default.
• W2994622122 cites W2795922861 @default.
• W2994622122 cites W2796258974 @default.
• W2994622122 cites W2804108711 @default.
• W2994622122 cites W2805180360 @default.
• W2994622122 cites W770714277 @default.
• W2994622122 doi "https://doi.org/10.1016/j.jaci.2019.08.043" @default.
• W2994622122 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7046077" @default.
• W2994622122 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31866099" @default.
• W2994622122 hasPublicationYear "2020" @default.
• W2994622122 type Work @default.
• W2994622122 sameAs 2994622122 @default.
• W2994622122 citedByCount "26" @default.
• W2994622122 countsByYear W29946221222020 @default.
• W2994622122 countsByYear W29946221222021 @default.
• W2994622122 countsByYear W29946221222022 @default.
• W2994622122 countsByYear W29946221222023 @default.
• W2994622122 crossrefType "journal-article" @default.
• W2994622122 hasAuthorship W2994622122A5002714937 @default.
• W2994622122 hasAuthorship W2994622122A5023824672 @default.
• W2994622122 hasAuthorship W2994622122A5026415610 @default.
• W2994622122 hasAuthorship W2994622122A5041039670 @default.
• W2994622122 hasAuthorship W2994622122A5043482439 @default.
• W2994622122 hasAuthorship W2994622122A5043763838 @default.
• W2994622122 hasAuthorship W2994622122A5048374080 @default.
• W2994622122 hasAuthorship W2994622122A5062887081 @default.
• W2994622122 hasAuthorship W2994622122A5075233055 @default.
• W2994622122 hasAuthorship W2994622122A5076055234 @default.
• W2994622122 hasAuthorship W2994622122A5076072202 @default.
• W2994622122 hasAuthorship W2994622122A5084365337 @default.
• W2994622122 hasBestOaLocation W29946221221 @default.
• W2994622122 hasConcept C119060515 @default.
• W2994622122 hasConcept C126322002 @default.
• W2994622122 hasConcept C203014093 @default.
• W2994622122 hasConcept C207480886 @default.
• W2994622122 hasConcept C2776042228 @default.
• W2994622122 hasConcept C2777697326 @default.
• W2994622122 hasConcept C2780333948 @default.
• W2994622122 hasConcept C2780510475 @default.
• W2994622122 hasConcept C2781018748 @default.
• W2994622122 hasConcept C2908647359 @default.
• W2994622122 hasConcept C71924100 @default.
• W2994622122 hasConcept C99454951 @default.
• W2994622122 hasConceptScore W2994622122C119060515 @default.
• W2994622122 hasConceptScore W2994622122C126322002 @default.

• next